Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2015 /
Investigational PD-L1–targeted immunotherapy safe for patients with triple-negative breast cancer

18th - 22nd Apr 2015

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.05.15
Views: 1882

Prof Leisha Emens - Johns Hopkins Kimmel Cancer Center, Baltimore, USA

Prof Emens talks to ecancertv at AACR 2015 about how an investigational immunotherapy, MPDL3280A, was safe, tolerable, and showed early signs of durable clinical activity in patients with metastatic triple-negative breast cancer.

Read the news story and watch the press conference for more.

Click here for comment on Emens' study by Prof Dr Louis Weiner (Lombardi Comprehensive Cancer Center, Washington D.C, USA).

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation